SYNOPSIS Myxin, a relatively new antibacterial and antifungal antibiotic, produced by a species of Sorangium, was used to investigate its effectiveness against some yeasts and dimorphic fungi associated with human diseases. Results indicated that the minimal fungicidal concentrations (MFC) of myxin for Candida albicans, C. krusei, C. parapsilosis, C. tropicalis, and Torulopsis glabrata were 0O39-6'25 ,ug/ml, and for C. guilliermondii and C. tropicalis 12-5-25 ,ug/ml. The MFC for Blastomyces dermatitidis and Sporothrix schenckii was 0-195 and 6 25 jig/ml, respectively. The MFC for these two systemic fungi for amphotericin B (fungizone) was 0-39-0-78 and 6 25 g/mIl. maintained on Phytone-yeast extract agar (BBL) and brain heart infusion agar (BHI, Difco), respectively, at 370C.
Coccidioides immitis was found to be very sensitive to myxin (MFC, ,ug/ml).
Myxin, a relatively new antibiotic, produced by a species of Sorangium (Peterson, Gillespie, and Cook, 1966) , has been reported to inhibit the growth of Gram-negative and Gram-positive bacteria, several plant pathogenic and saprophytic fungi, yeasts, and actinomyces (Peterson et al, 1966) . Recently, it has been observed that strains of Sorangium (= Lysobacter antibioticus, Christensen, 1973) inhibited the growth of a strain of Scopulariopsis brevicaulis, which was the aetiological agent of deep scopulariopsosis (Sekhon, Willans, and Harvey, 1974) . Despite thb broad known spectrum of activity of myxin, its effectiveness has not been determined against most 1-asparagine, 1-5 g; dextrose, l0 g; deionized distilled water, 1 litre; sterilized through membrane filter). The procedure used for the test was essentially the same as described in the Center for Disease Control's manual (Haley, 1972) . Tube number 1 contained 6 ml of broth and all the other tubes contained 5 ml. The myxin used in this study was obtained from Hoffman-LaRoche Inc, Nutley, New Jersey (RO 7-4488, Lot SM-4, contained 20% water). The amphotericin B (fungizone) was the product of E. R. (O 195,ug/ml) than to amphotericin B (0 39-78,ug/ml); whereas the MFCs for these two antibiotics for S. schenckii were the same (6 25 jug/ml).
This study indicates that low concentrations of myxin inhibit the growth of yeasts and the dimorphic fungi that cause blastomycosis, coccidioidomycosis, and sporotrichosis. In vivo studies are needed to find out whether myxin would be a useful systemic antifungal agent. Such new agents are needed, because amphotericin B and 5-fluorocytocine are sometimes not effective; for example, in a case of candida endophthalmitis, as described by Skidmore and Cockcroft (1974) . Also, in this study we have found that myxin yielded very promising results with respect to a strain of T. glabrata (PLM 305), which was otherwise found to be resistant to 5-fluorocytosine (2000 ,ug/ml; unpublished 
